Captrust Financial Advisors Buys 9,087 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Captrust Financial Advisors raised its stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 89.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,261 shares of the biotechnology company’s stock after buying an additional 9,087 shares during the period. Captrust Financial Advisors’ holdings in Aldeyra Therapeutics were worth $104,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ALDX. SG Americas Securities LLC bought a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at $38,000. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Aldeyra Therapeutics by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 88,122 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 6,944 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Aldeyra Therapeutics by 21.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company’s stock valued at $648,000 after purchasing an additional 34,885 shares during the last quarter. Panagora Asset Management Inc. bought a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at $200,000. Finally, Rhumbline Advisers grew its holdings in shares of Aldeyra Therapeutics by 20.1% during the 2nd quarter. Rhumbline Advisers now owns 76,981 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 12,907 shares during the last quarter. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Trading Up 3.3 %

Shares of ALDX opened at $5.06 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The firm has a fifty day simple moving average of $5.15 and a two-hundred day simple moving average of $4.74. Aldeyra Therapeutics, Inc has a twelve month low of $2.71 and a twelve month high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, hitting the consensus estimate of ($0.25). As a group, equities analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.